Company Overview
Aclaris Therapeutics, Inc. functions as a clinical-stage biopharmaceutical entity dedicated to discovering and developing novel molecule product candidates specifically designed to address immuno-inflammatory diseases within the United States. The company operates within the Healthcare sector, specifically the Biotechnology industry, which categorizes it as an entity focused on the innovation and advancement of biological treatments rather than traditional small-molecule pharmaceuticals. This operational scale is reflected in a total market capitalization of $434.70M, an annual revenue of $7.83M, and an employee base of 69 individuals. These financial figures indicate that the company maintains a mid-cap profile typical for early-to-mid stage biotechnology firms, where a significant portion of market value is derived from potential future pipeline assets rather than current earnings, and the revenue volume suggests a business still in a phase of limited commercialization or heavy research expenditure.
Financial Health
The company reported revenue of $7.83M for the trailing twelve months, a figure that contrasts sharply with a net income of -$64,923,000 and an EBITDA of -$74,035,000. The substantial gap between the modest revenue and the significant net loss reveals a cost structure heavily weighted toward research and development expenses, which is characteristic of clinical-stage entities that have not yet achieved commercial profitability. Free cash flow stands at -$30,631,876, indicating that the company is consuming cash to fund its operations and development activities, which limits immediate financial flexibility without access to external capital markets. All three reported margins reflect this operational phase: the gross margin is 0.0%, the operating margin is -1724.6%, and the profit margin is 0.0%. These negative or zero margin figures indicate that current revenue generation does not cover the direct costs of goods sold or the broader operating expenses required to sustain the clinical pipeline. On the liability side, the company holds $90.75M in cash against only $2.12M in debt, resulting in a debt-to-equity ratio of 2.05. While the debt-to-equity metric suggests leverage, the absolute cash position far exceeds debt obligations, creating a buffer that allows the firm to manage its solvency despite the negative operating margins. Furthermore, a current ratio of 3.36 demonstrates strong short-term liquidity, as the company possesses more than three times the liquid assets necessary to cover its current liabilities. Return on equity is reported at -50.2% and return on assets at -24.3%, metrics that reveal management is currently utilizing the company's equity and asset base to generate losses rather than returns, a common reality for biotechnology firms investing heavily in future product potential.
Valuation Assessment
Valuation metrics for Aclaris Therapeutics present a complex picture due to the lack of traditional profitability measures, with a P/E Ratio (TTM) listed as N/A and a forward P/E of -4.79. The absence of a trailing P/E and the negative forward P/E imply that the market is not valuing the stock based on current earnings, as the expected earnings trajectory remains deeply negative in the short term. Instead, the price-to-book ratio of 4.20 indicates a significant market premium over the company's book value, suggesting investors are pricing in the potential future value of the clinical pipeline rather than historical net assets. Alternative valuation multiples provide further insight, with a price-to-sales ratio of 55.55 and an EV/EBITDA of -4.65, suggesting the market is willing to pay a high multiple for every dollar of sales generated by the company. The stock's price volatility is contextualized by a 52-week high of $4.89 and a 52-week low of $1.05, indicating a wide trading range driven by the binary nature of clinical trial outcomes. The beta value of 0.87 suggests that the stock's price volatility is slightly lower than the broader market, though it still moves in tandem with general market sentiment.
Growth & Income
Growth metrics show a revenue growth of -85.9% year-over-year, while earnings growth is listed as N/A. The negative revenue growth indicates a contraction in sales, and the lack of earnings growth data reflects the company's inability to post positive earnings, implying that the business model is currently dependent on external funding rather than organic revenue expansion. As the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, meaning there are no distributions to shareholders. Consequently, the company reinvests all available resources, primarily from its substantial cash reserves, into research and development efforts rather than distributing income. The overall growth and income profile is characterized by a complete reliance on capital preservation and clinical advancement, with no current income stream or revenue expansion to support shareholder returns.